Rubin L A, Nelson D L
University of Toronto, Ontario.
Ann Intern Med. 1990 Oct 15;113(8):619-27. doi: 10.7326/0003-4819-113-8-619.
To review the biologic origin, functional characteristics, and current and potential clinical applications of a novel marker of immune system activation, the soluble interleukin-2 receptor (sIL-2R).
Studies reported since 1985 were identified by a computer search using MEDLINE as well as from bibliographies of published work.
Sixty-two reports on the clinical applications of the sIL-2R, largely from peer-reviewed journals, were identified. These reports address the utility and significance of sIL-2R measurements in various conditions. Basic scientific investigations delineating the biochemical and molecular features of the human interleukin-2 receptor complex and the sIL-2R protein were reviewed.
The validity of sIL-2R quantitation as an index of in-vivo immune system activation and its usefulness as a measure of disease activity and outcome were examined.
The quantitation of sIL-2R, a novel laboratory measure of in-vivo immune system activation, correlates reliably with disease activity in autoimmune inflammatory disorders, transplantation rejection, and specific infectious disorders. Markedly elevated serum sIL-2R levels are a particularly prominent feature of certain hematologic malignancies, such as human T lymphotropic retrovirus type I-associated adult T-cell leukemia and hairy cell leukemia, reflecting tumor burden and response to therapy. The sIL-2R level at disease onset may also reliably predict long-term prognosis in non-Hodgkin lymphoma, and it appears to provide an additional serologic measure in the assessment of clinical progression in patients with human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Studies have suggested that sIL-2R levels offer a rapid, reliable, and noninvasive measure of disease activity, response to therapy, and, in some cases, prognosis in a broad spectrum of conditions associated with T- or B-cell immune activation.
综述免疫系统激活的一种新型标志物——可溶性白细胞介素-2受体(sIL-2R)的生物学起源、功能特性以及当前和潜在的临床应用。
通过使用MEDLINE进行计算机检索以及从已发表著作的参考文献中识别自1985年以来报道的研究。
确定了62篇关于sIL-2R临床应用的报告,这些报告大多来自同行评审期刊。这些报告阐述了sIL-2R检测在各种情况下的实用性和意义。对描述人类白细胞介素-2受体复合物和sIL-2R蛋白的生化及分子特征的基础科学研究进行了综述。
检查了sIL-2R定量作为体内免疫系统激活指标的有效性及其作为疾病活动和预后衡量指标的有用性。
sIL-2R定量作为一种新型的体内免疫系统激活实验室检测方法,与自身免疫性炎症性疾病、移植排斥反应和特定感染性疾病的疾病活动度可靠相关。血清sIL-2R水平显著升高是某些血液系统恶性肿瘤(如人类嗜T淋巴细胞病毒I型相关的成人T细胞白血病和毛细胞白血病)的一个特别突出的特征,反映肿瘤负荷和对治疗的反应。疾病发作时的sIL-2R水平也可可靠地预测非霍奇金淋巴瘤的长期预后,并且它似乎为评估人类免疫缺陷病毒感染和获得性免疫缺陷综合征患者的临床进展提供了一种额外的血清学检测方法。
研究表明,sIL-2R水平为广泛的与T细胞或B细胞免疫激活相关的疾病的疾病活动度、对治疗的反应以及在某些情况下的预后提供了一种快速、可靠且非侵入性的检测方法。